Saturday, 29 December 2012

Hospital antibiotic use declines by 6% due to curbs

Report claims antibiotic use fell from 25% to 19%
China's national campaign to crack down on prescription drug abuse appears to be making progress, after figures revealed a drop of 6 percentage points in the use of antibiotics in hospitals from 2008 to 2011.
An annual report by the Chinese Academy of Social Sciences on China's pharmaceutical market showed top-level hospitals in 21 provinces reported antibiotics use dropped from 25 percent in 2008 to 19 percent in 2011.
"The report illustrates the success we've made in the campaign," said Zhu Hengpeng, senior associate of the Institute of Economics, at the Chinese Academy of Social Sciences.
"Antibiotics abuse drives up medicine costs," he added.
The side effects of antibiotics use can lead to more serious problems, including damage to organs, and disorders associated with the body's resistance to disease.
Many Chinese believe wrongly that antibiotics can reduce inflammation, meaning they are often misused to treat maladies like toothaches and fevers, according to experts.
In recent years, China attached growing importance to the issue, and have been urging hospitals to take more care when prescribing antibiotics.
In the latest move, it launched a surveillance system in July to document cases of antibiotic-resistant bacteria at 1,349 large public hospitals across the country.
Media reports have suggested that antibiotics overuse results in about 80,000 deaths in China a year, and could cost 80 billion yuan ($12.8 billion) to treat.
However, officials from the Ministry of Health said no reliable research can prove the numbers.
Elsewhere in the report, figures showed that antibiotics still account for a smaller proportion of drug misuse in China, compared with drugs acting on the nervous system, which increased by 1.6 percentage points in use and drugs for treating tumors, which rose 1.3 percentage points.
Statistics from several city and provincial health bureaus revealed that tumors have now became the top life-threatening disease in China.
In Beijing, one in four deaths was the result of a tumor in 2010, and incidence of breast cancer in Beijing jumped by 130 percent from 2000 to 2009.
Zhi Xiuyi, director of Capital Medical University's Department of Oncology, said that a combination of pollution, stress and modern lifestyles were contributing to the rises.
Apart from drug use, the report also listed the top 10 pharmaceutical companies now operating in China, in terms of market penetration of top-level hospitals.
The global giant AstraZeneca topped the list, half of which consisted of foreign companies.
Source: China Daily

Friday, 28 December 2012

Wuhan researchers develop oral vaccine for rabies

Affordable vaccine may help prevent rabies deaths in China
by Michael Woodhead
Researchers from Wuhan have helped develop a new vaccine for rabies that is based on the virus that causes kennel cough.
Publishing their research in the Journal of Virology, scientists from the State-key Laboratory of Agricultural Microbiology at the College of Veterinary Medicine, Huazhong Agricultural University, Wuhan say that untreated rabies virus infection is fatal and the disease causes 55,000 deaths a year. They note that vaccine and post-exposure treatment are effective in preventing rabies, but rabies vaccination and treatment have not been widely used in developing countries due to the high cost.
To try develop an effective and cost effective rabies vaccine they tried a new approach by using Parainfluenza virus 5 as a vaccine vector.  They note that Parainfluenza virus 5 is thought to contribute to kennel cough and kennel cough vaccines containing live PIV5 have been used in dogs for many years.
Therefore they tested a PIV5-vectored rabies vaccine in mice. A recombinaint PIV5 encoding RABV glycoprotein (G) (rPIV5-RV-G) was administrated to mice via intranasal (IN), intramuscular (IM) and oral inoculation. They found that  a single dose of the new vaccine was sufficient for 100% protection when administrated intranasally. The intramuscular route also provided very robust protection (90%-100%) against rabies. And intriguingly, the mice vaccinated orally with a single dose of vaccine showed a  50% survival rate, which is comparable to the 60% survival rate sen with the attenuated rabies vaccine.
"This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate the rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines," they conclude.
Source: Journal of Virology

Smoking fines double as Shanghai cracks down on tobacco

Smokers were fined more than $50,000 last year
The Shanghai city government has fined individuals and businesses 313,505 yuan ($50,267) over the first nine months of this year for violating the city's smoking regulations, the local health promotion authority announced at a press conference on Thursday.


The total was almost twice the amount the government fined over all of last year.

 As of the end of September, four regulation enforcement authorities conducted 230,531 inspections and fined 77 individuals and 179 public spaces, according to the Shanghai Municipal Health Promotion Committee. 

Under regulations introduced on March 1, 2010, smoking is prohibited in 13 types of public places, including hospitals, schools, museums and libraries, as well as on public transportation. The maximum fine for an individual violation in public spaces such as hospitals and schools is 200 yuan. Businesses can be fined as much as 30,000 yuan for failing to prevent smoking on the premises.

 Authorities at the district level have been enforcing smoking regulations more strictly this year at Internet cafes, restaurants and entertainment establishments - places where violations were most prevalent, said Gu Xiping, a press officer with the Shanghai Municipal Health Promotion Committee. 

According to the regulations, restaurants and bars larger than 150 square meters with more than 75 seats must confine smoking to designated areas. These establishments must also post no-smoking signs and remove items related to smoking, such as ashtrays, from non-smoking areas. 

The committee has also seen an increase this year in public involvement with the enforcement of the regulations. The number of volunteer inspectors had increased to 1,855 as of September, up from a total of 1,170 last year, according to the committee. 

"To raise public awareness about these regulations, we will continue to run promotion campaigns next year. We are also going to learn from the successful experiences of Hong Kong and other overseas cities," said Li Zhongyang, vice director of Shanghai Municipal Health Promotion Committee. 

"We hope that local residents will have more self-discipline and consider their own health and the health of other people when it comes to smoking," Li added.
Source: Global Times

Beijing hospital senior doctor critical after stabbing

Stabbing victim was vice president of Pinggu District Hospital
A vice president of a hospital was slashed by an unidentified man near the hospital in Pinggu district, Beijing Thursday morning, local media reported.
At around 6am, Wang Jianyun, vice president and chief physician of the Pinggu District Hospital, was attacked on his way to the hospital. While investigation is still ongoing, police suspect two men attacked Wang before escaping by car.
A witness said a group of old men playing the shuttlecock found Wang bleeding and rushed him to the hospital for emergency treatment.
Police cordoned off the area and obtained footages from surveillance cameras overlooking the road. It is still uncertain if the video images are clear because it was still dark outside when the doctor was stabbed.
Hospital staff refused to comment on Wang's condition, citing employee confidentiality, but reports indicated that Wang suffered multiple wounds in his lungs. He is now in the intensive care unit after a surgery.
Source: Sina English

One child policy exacerbates diabetes epidemic in China

First borns gain more weight and gain it faster, which may create an epidemic of diabetes in China
Diabetes in China, which is emerging as a major health issue in the country is probably being aggravated by its one-child policy, experts observe.
The Chinese Government said that about 100 million families have just one child, which translates into an equal number of first borns, a status that researchers are finding may be linked to conditions that raise obesity risk, Chong Yap Seng, a scientist at Singapore’s National University Hospital, said.
Dr Chong and colleagues in Beijing and Southampton, England, are studying the biological mechanisms that have conspired with diet and lifestyle changes to produce 92.3 million diabetics in China, almost four times as many as in the United States.
Chong said that first borns gain weight faster and are bigger as adults, a trajectory that increases obesity risk and may explain why China’s diabetes prevalence has more than tripled in a decade, the report said.
Sales of diabetes medicines in China will expand 20 percent a year to reach 3.2 billion dollars by 2016, consulting firm IMS Health said, it said.
The one-child policy was introduced in 1979 to curb a population growing 1.4 percent a year and to promote prosperity, it added.
According to the report, some exceptions to the policy are allowed, such as permitting rural families to have a second child if the first is a girl. Those who can afford to can have a second or third baby by paying a fine.
Rising numbers of diabetics, though, are costing China’s economy 26 billion dollars annually in medical care and lost productivity, according to the International Diabetes Federation.
The prevalence of diabetes in China, a nation of 1.34 billion people, is 8.8 percent, the report said.
The U.S. has a diabetes prevalence of 9.3 percent and 24.1 million sufferers, according to federation estimates released last month.
Within 18 years, China is projected to have 130 million sufferers of Type 2 diabetes, the form of the disease in which the body stops responding properly to the hormone insulin, according to the Brussels-based federation.
The disease is already killing 1.2 million Chinese a year because of kidney failure, heart attack and other associated conditions, it said in a recent report.
A 2010 study by researchers in Brazil, Britain and Italy published in PLOS One found that birth order is associated with increased body mass, higher levels of fat and metabolic risk in young adult men in Brazil, the report added.
Source: Healthcare Asia

Rich doctor scorned for being unfilial son

A high-earning doctor in south China who refuses to support his ill mother is facing fierce backlash in the country that traditionally values filial piety. 
Yang Xiaomin, an associate professor at Hainan Medical University and a doctor with HMU's Affiliated Hospital, has refused to provide 1,500 yuan ($240) a month to cover his septuagenarian mother's medical costs and daily expenses.
Yang refuses to be his mother's caretaker, saying he "cannot afford to hire a nanny."
When his sister stepped in to take care of their mother and asked for money to help cover the costs, he refused even though the sum is only about one-seventh of his monthly salary.
Yang has suggested sending his mother, surnamed Li, to a local nursing home, threatening to sever all ties with Li if she doesn't.
"I have devoted my whole life to bringing up my son. I can't believe he would treat me like this," Li sobbed.
Yang's behavior has angered netizens and sparked a widespread discussion on the state of morality in China. One media report about the case has been forwarded more than 1,800 times on Twitter-like Sina Weibo, with irate netizens lashing out at his disrespectful behavior.
"He doesn't deserve to be called a human being!" wrote Weibo user "buqieryu."
"This is unbelievable! How do you expect someone with low moral standards to be a good doctor?" wrote "yuanshanyouwu."
Since the case began circulating on Weibo, Yang has been suspended from his positions at HMU and the hospital.
This, however, is not the only case that has drawn Chinese people's attention to the topic of filial piety recently. Earlier this month, a 91-year-old mother was beaten by her son and daughter-in-law and kicked out of her family's home simply because she wanted to have a bowl of porridge instead of noodles, her staple food for the past 22 years.
Another case of parent abuse was exposed via Weibo, in which a centenarian, surnamed Jiang, was living in a pigsty in Guanyun County, Lianyungang City, in Jiangsu Province.
Jiang, whose five sons and three daughters were supposed to take turns caring for her, has been living with pigs for the past three years. One of her sons insists that Jiang wanted to live with the pigs.
These cases reflect the disappearance of the traditional value of filial piety in a country with a fast-growing economy, said Xia Xueluan, a professor with the Department of Sociology of Peking University.
"In China, there are many who ignore the moral value of showing filial piety to parents, such as those often seen in property disputes with their parents," Xia said.
China is going through economic and social restructuring. Amid these changes, many are chasing money and leaving behind traditional Chinese values, including those regarding family relations, he said.
The government needs to do more work in moral education, especially in a graying China where filial piety is disappearing and senior citizens face lots of psychological problems, he added.
China's population is rapidly aging. By the end of 2011, 185 million people in China were aged 60 or above, and the number is expected to further rise to account for about 30 percent of China's total population of nearly 1.4 billion by the middle of this century.
The Chinese government has been increasing people's awareness of the importance of helping the elderly and restoring the traditional value of filial piety. In July, the Standing Committee of the National People's Congress, the country's top legislature, reviewed an amendment to China's Law on the Protection of the Rights and Interests of the Elderly for the first time.
The amendment added an item that asks sons and daughters to go home often to see their aging family members, which gained strong support from the Chinese people.
But Xia said this is far from adequate.
"In addition to laws and regulations, the government should boost traditional morality education. It should also consider moral standards when selecting government officials and thus, drive them to set good examples for the general public in terms of morality," he said.
Source: Xinhua

China healthcare: huge market, huge risks for western multinationals

by Barry S. Cohen
It's little wonder that multinational health care companies (MNCs) may be salivating at the opportunities in China:

1) By 2016 China is expected to be the second-largest drug market, forecast to reach nearly $165 billion that year

2) During the next several years the Chinese drug market is supposed to grow at a rate of 15% to 18% a year compared to little or no gains for the Western countries

3) Growing affluence is permitting many Chinese to pay out of pocket or pay high insurance deductibles to gain access to innovative Western medicine

4) China needs new drugs to treat higher than average incidences of hepatitis B and neck and head cancers. China also has growth potential for drugs to treat arthritis, diabetes, osteoporosis, high blood pressure, high cholesterol, depression HIV/AIDS.

However, all that glitters may not be gold. The chance of a recession as well as internal politics could make it difficult for the multinational pharmaceutical companies to make strong headway into the Chinese market. Nowhere in the world are the pressures greater to expand access to better health care while at the same time controlling costs.

Examples abound. One policy decision eliminated differential pricing on approximately 100 drugs MNCs sold into China. For nearly two decades, these drugs had benefited from special pricing as part of an agreement between the Chinese government and the pharmaceutical industry. Furthermore, a blind bid and tender process reduced prices on some drugs by up to 90%. MNCs watched as domestic Chinese pharmaceutical companies bid prices down in an effort to use volume gains to offset collapsing margins.

Despite the caution flags, large MNCs continue to devote substantial resources to cracking the Chinese market. Both Pfizer and GlaxoSmithKline have made major moves to re-orient sales resources away from developed economies towards China. Eli Lilly and Novartis , among others, have opened new R&D facilities in China, primarily in Shanghai. And given the country's mammoth diabetes problem, Sanofi is moving deeper into the country. The company's Lantus insulin product is estimated to have 17% of the Chinese market.

Large pharmaceutical companies hoping to stake a claim in China may be eyeing two of the country's largest medical research testing companies as a vehicle to gain entry. Both WuXi PharmaTech  and ShangPharma have been mentioned as possible takeover targets.

Even insurance company WellPoint has announced its entry with the hopes that it can develop a private healthcare insurance business. And medical device companies like Boston Scientific, Johnson & Johnson and Medtronic are also aggressively expanding into China. For more information about stocks in this space, our real time trading reports help investors identify opportunities before they happen.
Source: MSN Money

Chinese students sent to Nebraska to study medicine

Yang Hu is one of a select few students sponsored to study medicine in the US
by Paul Goodsell
Yang Hu is one of the first Chinese students chosen to enroll in the special program at the University of Nebraska Medical Center.
Going to an American medical school is more than a great opportunity for Yang. The program she joined is also a source of pride for UNMC and an example of the med center's growing international reputation.
While thousands of Chinese students already are at American medical schools for doctoral programs, research or short-term clinical rotations, the UNMC program is different. Only in Omaha does the Chinese government pick up the tab for its students to earn a four-year U.S. medical degree or a similar professional diploma in fields like pharmacy or physical therapy.
Besides bringing in tuition revenue, university officials say, they hope the students will establish relationships with UNMC that could lead to future research partnerships and other ties with China, the economic powerhouse that is expected to continue its rapid growth and increasing influence in the coming decades.
“These students will be leaders of Chinese health care,” said Jialin Zheng, a UNMC professor who heads UNMC's Asia Pacific Rim development program. “They will be ambassadors to future collaborations.”
For now, however, they are merely 20-something students wrestling with rigorous coursework, language challenges and an unfamiliar culture.
Yang and her fellow Chinese students have had to adjust to a different educational system and adapt to the American approach to health care.
They have stared blankly at American restaurant menus, worn costumes to Halloween parties and spent Thanksgivings with new Nebraska friends.
One is exploring Christianity after growing up as an atheist. Several have learned to drive.
The experience has “really helped me to broaden my horizon,” said Xin Zhang, a 26-year-old physical therapy student from Xi'an.
Xin and Yimei Huang, a pharmacy student from Chengdu, started at UNMC in 2011. This year, Yang and Lei Yu from Chengdu both entered the medical school.
The scholarship program is one element of the Shanghai-U.S. Health Science Initiative formalized in August when Nebraska Gov. Dave Heineman was in China on a trade mission. UNMC officials describe the broader pact as one of the most extensive partnerships between U.S. and Chinese academic institutions.
UNMC Chancellor Harold Maurer said the med center has ties with China that are envied by top U.S. universities. At a recent meeting with leading U.S. medical schools and the Chinese government, he said, “it was clear that UNMC is probably one of the best known U.S. institutions in China.”

Other schools such as Duke University asked the Chinese about why they were working so much with Nebraska, Maurer said. The answer: UNMC takes good care of its Chinese students and teaches them well. In addition, the Chinese noted, it doesn't cost as much to go to school in Nebraska.
With the new program, university officials have begun slowly, carefully selecting students for their English language ability and above-average test scores.
When fully implemented, there will be 10 new students arriving in Omaha each August — two in each of five areas: medicine, pharmacy, physical therapy, dentistry and nursing.
Read more: World Herald

There can be no real health reform without political reform

by Yanzhong Huang, Senior Fellow for Global Health
In April 2012, the director of the State Council Health Care Reform Office announced that targets set in the three-year plan for China's health-care reform had been accomplished on schedule.
There is no denying that the reform has led to expanded health insurance coverage and increased provision of public health services—it has also contributed to the strengthening of grassroots healthcare institutions. However, there has been at best mixed success in reforming the essential drug system. The past year was supposed to be a year of deepening health-care reform. The government selected about 300 pilot counties and cities for reforming public hospitals, which is considered the most important component of healthcare reform. It also announced plans to raise the reimbursement level for catastrophic illness to more than 50 percent, which is an important step toward reducing the share of out-of-pocket payments to 30 percent by 2015. Despite this, the reform has not fundamentally solved the problem of access and affordability. The officially stated 95 percent coverage rate contradicts the fact that more than 200 million migrant workers are actually not covered in China. Meanwhile, disintegrating business ethics and lack of regulatory capabilities have made food safety an unpredicted concern in China.
Driven by the need to maintain legitimacy and to stimulate domestic consumption, the new Chinese leadership is expected to commit to the building a social safety net in the coming years. For health-care reform to succeed, the new leaders have to demonstrate significant progress in reforming the public hospitals and make health care more affordable. In the absence of fundamental changes in public hospitals' financing and management structures, health-care costs will likely continue to increase rapidly. This could be exacerbated by population aging and the growing burden of chronic noncommunicable diseases (NCDs). Today, more than 80 percent of the mortality in China is attributed to NCDs, which is significantly higher than the world average (63 percent). So far, the government has not adopted a proactive approach to addressing NCDs and their risk factors (e.g., tobacco use). Sustained government funding for the healthcare sector is also threatened by local public financing problems. Local governments, which provide the lion's share of government health spending, still do not have the incentives and capabilities to effectively implement important reform measures. A fundamental overhaul of China's health sector therefore entails reforming China's archaic political system.
Read more: Council on Foreign Relations

Thursday, 27 December 2012

My take on China's health white paper

by Michael Woodhead, Editor, CMN
China has released a lengthy white paper setting out its current health situation, the state of play on health reforms and setting the ambitious target of establishing 'a sound basic medical and health system covering both urban and rural residents by 2020, so as to ensure that everyone enjoys access to basic medical and health services'.
The white paper cites some mind boggling figures: 2,500 billion yuan spent on health annually and 6 billion outpatient visits a year. The country has  2.5 million doctors and 5 million hospital beds, if the figures are to be believed (many of these doctors are public health doctors not working in front line clinical care).
The white paper has a generally positive spin on the health of Chinese people, saying the health system has contributed to increasing life expectancy and is coping with a large increase in hospital stays. It also makes much of the limited reforms to medical insurance, claiming that 95% of people have basic medical insurance and that out of pocket expenses have decreased from 58% to 35% (of what it is not clear).
At least it is honest in acknowledging that health care reform in China is going to be complicated and  arduous, and faces many barriers. My own take on the white paper is that it cites a lot of figures but doesn't really say exactly how the reforms are going to be implemented.
The challenges for China's health system reform fall into four main area: capacity, structure, funding and standards.

1. In terms of capacity, China (like all countries) is facing a large increase in both usage and expectation for healthcare services. Demographics are especially bad for China, which faces an ageing population that is not supported by a younger generation due to the one child policy. Despite having a million hospitals, China does not have the capacity to provide good healthcare to the whole population - especially in regional and rural areas. One of the main reasons is workforce: there simply aren't enough doctors, nurses and other healthcare staff to provide care for a billion people. It has been estimated that China needs 200,000 extra paediatricians, for example. Therefore workforce training and deployment are major issues for China. The white paper also says little about allowing foreign companies and organisations to set up in China and provide health services - this is one way in which capacity (and workforce) could be supplemented.

2. Structure. China's health system is based around hospitals, and this severely limits its capacity to provide care for people with chronic disease, and also to provide continuity of care. China needs a primary care system, and there are some moves in that direction underway already. However, it remains to be seen whether China can really reform its hospital based health system and wean patients away from hospitals. China also needs to look at using other healthcare professionals in wider roles - not barefoot doctors but at the provision of physiotherapists, pharmacists, extended care nurses etc.

3. Funding. If China is to provide a universal healthcare system for all, it is going to need massive funding. The white paper is not clear on exactly how this will be done. It mentions the moves towards new medical insurance schemes, such as the rural cooperative medical insurance system, and also the new pilot programs to cover catastrophic diseases such as cancer. These are commendable moves in the right direction, but it is very early days yet. As with most things in China, there is little transparency or accountability in the health system. The white paper does not say much on how China will allocate funding funding for health, and exactly where it will go. Will there be more money for rural clinics and hospitals? Who will provide the funding at provincial and county level and ensure that funds are directed to clinical services? How will China balance the mix of public and private health cover and how will it set the levels of cover and premiums? In the white paper, China claims an impressive 95% coverage for basic medical insurance. However, this fails to acknowledge that this cover is broad but shallow - it does not cover basic medical care for anyone with a chronic or catastrophic illness. The Ministry of Health may wish to provide medical cover for all, but the real power lies with the Ministry of Finance and with provincial and local leaders who will provide the funding (or not).

4. Standards and quality. China's health reforms will have to tackle the issues of poor and uneven quality in many areas of the health system - from skill standards of practitioners to quality of drugs and medical products and also the wider issue of quality of environment.
The newly affluent Chinese public have increasing expectations of health services, but these are not being met. Many question the clinical and caring skills of doctors and nurses, and there is huge frustration over the 'no pay no care' situation, as witnessed by the violent attacks on doctors and nurses. China needs to ensure that standards are set and adhered to in all areas of clinical care. This also applies to area such as pharmaceuticals and medical products - there have been many well publicised cases of substandard drugs, blood products and food contamination. Often China's response to failings has been draconian - jailing or even executing those responsible. This is not the way to run a modern health system - there is a need for open-ness, professionalism and accountability. The same applies to public health issues such as pollution and food standards. When air pollution levels are deemed a state secret there is little hope of improving respiratory health!

Well, these are just a few of my initial thoughts on the white paper. It has set a hugely ambitious goal of establishing universal, affordable and good quality care for all Chinese. This is commendable and potentially achievable, given China's track record in 'moving heaven and earth' in other areas. However, it will require huge change and will upset many vested interests in  local government, health institutions and businesses. Health reform will also require huge changes in expectations from the Chinese public - they can no longer expect to receive 'walk in' care at a hospital and be provided with a pill (or infusion) for every ill. If the health reforms can get the Chinese public to start seeing GPs by appointment by 2020 and accepting that antibiotics don't cure all fevers then they will have achieved a huge turnaround.

Salt substitution reduces hypertension in Chinese people

Blood pressure was lowered by 4mm after replacing some sodium chloride with potassium chloride
by Michael Woodhead
Replacing regular salt with a potassium chloride-based  alternative may be an effective additional way to lower blood pressure for Chinese hypertensive patients, a study has shown.
Professor Zhou Beufan and colleagues from Beijing assessed the potential efficacy of replacing sodium chloride with potassium chloride for preventing hypertension in patients with hypertension and also in normotensive family member controls.
They conducted a double-blind, randomized controlled trial among 200 families in rural China to establish the two-year effects of a reduced-sodium, high-potassium salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate) compared with normal salt (100% sodium chloride) on blood pressure.
Of the 372 people who completed the study, the mean overall difference in blood pressure between the two groups at the 24-month follow-up was 2 mm Hg for systolic BP and  and 2 mm Hg for diastolic BP. For the people with hypertension, there was a 4mm Hg overall decrease in systolic blood pressure, but diastolic blood pressure was not affected by salt use in the hypertensive group.
The researchers conclude that salt substitution lowers systolic blood pressure in hypertensive patients and lowers both systolic and diastolic blood pressure in normotensive controls.
"Salt substitution, therefore, may be an effective adjuvant therapy for hypertensive patients and [has] potential efficacy in preventing hypertension in normotensive individuals," they say.
Source: Journal of Human Hypertension

End of life care discussion in China

Discussions about dignified dying are no longer a taboo in China
by Zhao Xu
It's been nearly six weeks since her 82-year-old mother died, but Huang Yuan still cringes when she remembers the glimpses she caught of the elderly woman behind the thick glass wall of the intensive care unit. It's a wall that separates, often once and for all, the realm of the living and the immediate, dark corridor leading to the world of death.
"My mother had lost the ability to expectorate. So to prevent her from choking on the phlegm building up in her throat, the doctors decided to place her face down," said Huang, taking long, hard pauses between words as she tried to simultaneously recall but also blunt the painful memories.
"Mom remained there, her head hanging over the edge of the bed and her forehead supported by a cushioned chair. The combined effects of the illness and gravity had given her a swollen face. It was so bad she could barely open her eyes. Moreover, her lips had been constantly acted on by the same forces, to the point that even when she was temporarily restored to her normal, lying position on the bed, they were fixed in a terrible expression, parted, elongated."
The intense suffering was witnessed by the dying woman's seven heartbroken daughters. It sparked a long, often furious, yet ultimately inconclusive, debate among them as to whether their mother was paying too high a price for a chance of recovery so slim that it almost didn't exist.
"What did she want - life or relief from the pain? We are still haunted by that question and will be forever," said Huang.
"Maybe they didn't have to decide and suffer perennial torment over whatever decision they made," said retired cardiologist Luo Diandian. Luo is now a writer whose own experience of her mother-in-law's death, allied to her exposure to Western medical ideas and practices regarding terminal illnesses, combined to make her a strong advocate of so-called Living Wills.
"As the names suggests, a living will is a clear expression of what a person wants and, just as importantly, doesn't want, when it comes to the handling of his or her illness in its very final stage. The core centers on the medical treatment," she said. "For example, a person can specify whether or not he or she will opt for all, or just a certain part of the life-support measures, ranging from being fed by tube and mechanical ventilation, to dialysis and defibrilation."
Two things are emphasized when a person is considering making a will of this kind. First, a living will can be changed whenever the testator wishes, with the final version being the last one made while he or she was still capable of doing so, either in written or oral form. Second, for a living will to be officially valid, the testator must be diagnosed with a terminal illness and a clinically estimated life span of less than six months. In addition, the person must not have expressed any wishes to the contrary.
In some parts of the United States and Canada, the concept of the living will has become so entrenched that it's now considered a basic human right and is legally protected, according to Luo. Although making a will is not compulsory, people are likely to be advised to seriously consider writing one, once they enter adulthood.
So why don't more people embrace this concept and assert control over their exit from the world? The answer is complicated and can be rendered impenetrable by the welter of implications relating to death.
'Bound by sensitivity'
Weng Li, an attending physician at Peking Union Medical College Hospital in Beijing, where Wang's mother spent her last days, wrestles with complexities such as this every day.
"Unlike their Western counterparts, who are legally obliged to tell the full truth directly to their patients, Chinese doctors seem to be 'bound by sensitivity' to conceal the painful reality from their patients, but instead will tell the family members something closer to the truth," conceded Weng. "It's a cultural issue, but when it comes to writing a living will, the underlying contradiction is: How can you ask someone to seriously consider the option, while making every effort to convince him or her that they are not going to die?"
He said that neither the doctors nor the relatives should be blamed. "For the majority of Chinese people, death is still too frightening a thought to face honestly. You might be doing the patient a disservice by plunging them into an ocean of fear where they will simply drown," he said.
Huang, whose father died of gastric cardia cancer in 2008, is a believer in "not telling".
"When the cancer was first diagnosed, we were told to be prepared for his death within six months, but dad lasted another three and half years," she said. "Throughout that time, we never mentioned it and he never really asked. I had the feeling that he had started to sense the deadline approaching, but that wasn't until the very end of his life. Keep him in the dark, or under the sun? It could be both."
In other words, the significance of "the will" notwithstanding, a dying person's often implicitly expressed desire to talk only about survival should be fully respected. And in this case, to be an accomplice in the denial of a hard and imminent truth may be the ultimate demonstration of love, even though it often exacts a tremendous emotional price on those closest to the dying and may deprive both parties of the chance of saying a proper goodbye.
In 2006, Luo set up a website, www.xzyzy.com, and started recruiting volunteers to spread her message. But, despite her continuing efforts, she has only managed to have brochures displayed in one private hospital in Beijing. Refusal is often based on the grounds that such a graphic representation of death, often unsparing in its evaluation of each and every treatment and the potential revival measures required, is potentially offensive and may be at variance with a doctor's mission to save lives.
"When the odds are overwhelmingly stacked against the patient, and death becomes destiny, a doctor's first priority automatically changes from enabling life to easing its end. It's also the time when the doctor should stop being 'aggressive', take a conscious step back and let the patient decide what's the best for him or her," said Liu Duanqi, a former director of the oncology department at Beijing's General Army Hospital, who spent his working life treating terminal cancer patients. "Sadly, in reality, the majority of patients are dragged by their 'ever-dutiful' doctors all the way through their last, physically and emotionally ravaging journey."
There's a tendency to blame the profit motive, because hospitals are often attacked for being driven by financial self-interest, and there's also a fear that some doctors may "persuade" dying patients to undergo harsh, experimental treatment for research purposes, he said.
However, according to Liu, the lack of education about death provided to Chinese medical students is at the heart of the problem.
"Ask a patient whether he wants to live or not and that person will most definitely say yes. But, if you change the question to whether he is willing to endure this or that in order to live just one more week, you might get a different answer. With all their professional knowledge, empathy and skills, doctors can take a guiding role, even from behind the scenes," said Liu.
The reluctance, or possibly inability, of many Chinese doctors to engage patients and their families in sensitive and meaningful discussion about the range of possible choices and potential results often leads to unfounded hope, sudden disillusionment and ultimately anger and despair, according to Liu.
"Despite their general feeling of being wronged, these doctors have, in effect, robbed their dying patients of their last opportunity to make sensible, well-informed decisions," he said.
"And for people with high-level medical insurance, to prolong the process of death at the taxpayers' expense constitutes, for me, a form of social injustice."
The depth of understanding and the courage shown by a person in the face of impending death is the best and most generous parting gift those left behind will ever receive.
Chen Zuobing, director of the emergency department at the First Hospital of Zhejiang University in Hangzhou, East China, knows all about that. His father was diagnosed with terminal-stage peritoneal cancer in July, 2011. After a short, yet intense period of wavering that proved all-consuming, Chen helped his 77-year-old father face the stark reality.
After deciding against chemotherapy, the elderly man left the hospital where his son worked and returned to his home in the countryside. He planted pumpkins and played with the neighborhood children until his deteriorating health prevented him from doing so. Nine months later, in April, he died quietly at home.
"I gave my father the choice and he proved himself a hero," said Chen.
While stressing that she puts quality of life above quantity, Luo insisted that there's absolutely nothing wrong if a person decides "not to become reconciled to the idea of mortality, and to fight to the very bitter end".
"The idea of a graceful death has always been controversial. To me, the commitment to continued existence, no matter how much pain it entails, requires just as much courage," she said. "The purpose of a living will is to fulfill one's last wishes. Any decision that is truly heartfelt is heroic and fully dignified."
Read more: China Daily

Monday, 24 December 2012

China sets up national cancer registries

Registry will allow Chinese doctors to understand trends in cancer
China is setting up a national cancer registry to fully understand the extent of the disease in the country and to help improve cancer prevention policies.
Chen Wanqing, deputy director of the national cancer registry center, under the Ministry of Health, said so far the government-funded project has set up more than 220 surveillance sites across the mainland, covering some 200 million people.
The sites include health institutions, specialized cancer hospitals, research institutions, and public health institutions, he said.
"Accurate cancer registration and monitoring is crucial for effective cancer prevention and control. This new system will involve the gathering of all kinds of cancer-related information," he told China Daily.
He called the new registry a long-term and systematic collection of data about cancer and tumor diseases, which will gather information on diagnostic findings, patient history, treatment progress and the status of cancer patients nationwide.
Qiao Youlin, vice-chairman of the expert board for early detection and treatment of cancers at the Ministry of Health, said the system will be able to gauge cancer trends and patterns from which it will be possible to better allocate resources, improve research and evaluate and improve cancer control programs.
But he added that the project will need the full support of all community-level medical service providers to work.
"Data collected at the grassroots levels represents the most accurate picture of the extent of the disease in China," Qiao noted.
Those currently on the registry are mainly those who hold a hukou (residence permit), but information on the large migrant population is missing, Chen added.
"It's hard to ensure the quality of the data, particularly in rural and run-down areas," he said.
Due to the sheer size of the population, Chen said, it would be hard for the registry to ensure coverage of every area.
"But we can still make a reasonably accurate calculation of the extent of the disease across the country, through quality coverage of regional data," he added.
Various European countries already have national cancer registries, which have managed to gather reliable findings on total cancer numbers.
In the United States, national cancer information is practically guaranteed through the Cancer Registries Amendment Act, which requires all institutions to register the information.
Chen urged medical institutions across China to support the new initiative by reporting cancer cases and any related data to the registry.
According to the Ministry of Health, there are 2.8 million new cancer cases on the Chinese mainland each year and the number is expected to reach 3.8 million within the next decade.
"Cancer has been on the rise, both in terms of incidence and death rate, over the past 20 years," said Chen.
He said that there are also changing patterns in those numbers.
Previously, Chinese were more susceptible to those so-called "poor cancers", such as liver, stomach, and esophagus cancers, according to data so far from the registry.
But as the country's wealth has continued to grow, there are increasing cases of what people call "rich cancers", like lung, breast, and colorectal cancers, he added.
Read more: China Daily

Immunisation halts Xinjiang polio outbreak

Immunisation has helped curb an outbreak of polio that affected 21 people and caused one death
WHO has confirmed that the Xinjiang region is clear of disease after last year's outbreak
China's disease control authorities will continue supporting the Xinjiang Uygur autonomous region to keep the region polio-free, a senior official has said.
Wang Yu, who heads the Chinese Center for Disease Control and Prevention, made the promise at a media event on Tuesday in Beijing to mark Xinjiang's continued polio-free status, which was confirmed by the World Health Organization at the end of last month.
Last year, there was an outbreak of polio in Xinjiang that entered the region from abroad. The 21 cases detected between August and October 2011 resulted in one death, and 17 people, including eight children, were paralyzed, according to the Ministry of Health.
Polio, or poliomyelitis, is a virus that infects the brain and spinal cord, mostly in children younger than 5 years old. One in every 200 cases leads to paralysis, usually of the legs.
"We've learned a lesson and will expand routine vaccinations in the area to avert future outbreaks," Wang said.
He said previous Chinese CDC studies showed that only 60 to 70 percent of Xinjiang residents had been vaccinated against polio, but 85 percent should be vaccinated to ward off an outbreak.
"In some areas the rate could be as low as 50 percent," he said.
In response, "the central government has allocated 160 million yuan ($25.7 million) to improve local public health services", Wang said.
Vaccination agencies will all be equipped with appliances to store vaccines at the necessary low temperatures, he said.
A suspected-case reporting system will be established at local hospitals to detect possible infections as soon as possible, he added.
In addition, border surveillance will be beefed up to prevent polio from entering China from abroad, he said.
According to Luo Huiming, deputy director of the National Immunization Program under the Chinese CDC, the outbreak last year was the first to come from abroad since 2000.
Because Xinjiang borders Pakistan and Afghanistan, where polio is endemic, "it's still at risk of infections, which know no boundaries", Luo said.
"We have to ensure comprehensive polio vaccination in the area to protect people from the disease," he said, adding that greater efforts should be made to raise vaccination awareness, particularly among ethnic groups.
"Thanks to assistance from the WHO and UNICEF, we launched a massive polio vaccination program in Xinjiang and regained the polio-free status within a short time," he said.
Five large-scale vaccination campaigns have been carried out in Xinjiang between September 2011 and April 2012, and at least 43 million doses of polio vaccine were given to children and adults.
According to the WHO, Chinese governments at all levels spent more than 340 million yuan for the response effort.
Michael O'Leary, the WHO representative in China, said that the 2011 polio outbreak showed that no place was safe until the crippling and lethal infection is eradicated worldwide.
With vaccination being the only means of prevention, it's crucial to strive for and maintain high immunization coverage, he added.
Luo Huiming agreed and recalled some difficulties during the massive vaccination campaigns.
Some local people refused at first to get vaccinated because of ethnic traditions, he said.
"Some even confused vaccination with family planning — the two sound similar in Chinese," he said.
"But with great patience we informed them of the importance of vaccination, and most finally said yes," he said, adding that the vaccination programs were free and voluntary.
A 33-year-old Uygur resident of Kashgar, Xinjiang, who gave his name as Parhat, was vaccinated during the campaigns.
"People younger than 40 in southern Xinjiang were advised to get the polio vaccine, so I did. I took the 'sugar pill' vaccine twice for free at the community center since last September," he said.
"Before taking the vaccine, I read and signed the notice about possible side effects after taking the pill. I had a fever after taking the vaccine, but the day after I was fine," he said.
Source: China Daily

Making a million from second hand medical equipment

Golden Meditech bought up old medical equipment from Japanese hospitals and sold it to Chinese hospitals
Kam Yuen occupies one of the largest offices of any chief executive in Hong Kong, on the 46th floor of the IM Pei-designed Bank of China building with views of the harbour and the hills of the city. An exercise bicycle stands behind a leather couch and massage chairs, while gold figures are placed on tables and window ledges. The figures are there for luck. Mr Kam is a great believer in luck, particularly his own.
He might well be, given that he founded two companies, Golden Meditech Holdings and China Cord Blood Corp, both of which are now listed. Shan Weijian, the former rainmaker of US buyout group TPG, has a stake in the first and KKR a stake in the second. Analysts estimate Mr Kam could be worth US$100m, based on his shareholding in Golden Meditech alone.
Mr Kam is the face of the new China, personifying both its strengths and limitations. Like many entrepreneurs, he made his fortune by spotting an arbitrage rather than by coming up with a breakthrough in product innovation or technology.
And while Mr Kam succeeded largely through his own initiative rather than through connections, today he is courted by princelings, and his ties with influential people help his business flourish.
“I have never thought I would not succeed,” he says, waving a cigarette.
Mr Kam, who is 51 though he looks far younger, grew up in Beijing. Ignoring his parents’ wish that he become a doctor, he studied at one of the city’s foreign language institutes. Having failed to learn English, Mr Kam attempted Japanese more successfully.
Upon completing his courses, he joined a metals trading state-owned enterprise, Minmetals, and was sent to Japan in the late 1980s. Tokyo at that time was probably the most expensive city in the world, and as a junior employee
of a Chinese state-owned enterprise, the young worker received a pittance.
“I was paid Rmb70 per month,” he recalls. “I wanted to be more independent.”
So Mr Kam cast about for a more lucrative means to support himself. He soon discovered that Japanese hospitals were constantly discarding medical equipment and replacing working machines with the latest generation of medical equipment – paying waste removal firms good money to get rid of the older models in the process.
The Japanese proclivity to throw out what anywhere else would be considered perfectly respectable goods from cars to couches is well known. But Mr Kam saw the business potential in this proclivity.
He went round to dozens of Japanese hospitals and convinced them to give him their used X-ray, ultrasound and other machines for free and then sold them to Chinese hospitals.
At the time Chinese hospitals had imaging devices that were only black and white; the imported equipment with their superior imaging technology sold very quickly. “There was no colour in China. It made the Japanese feel good,” he recalls. “I made them feel that they were helping China. I became a millionaire very quickly.”
Eventually, though, the magnanimity wore thin and Mr Kam says he was told he ought to begin paying for the equipment he was acquiring at no cost. That was a problem for him because he received local currency when he sold the equipment to Chinese hospitals while he needed yen to pay the Japanese. So he had to come up with something to sell in Japan to earn currency there.
Mr Kam, a devout Buddhist, spotted potential in an unlikely quarter . Japanese temples do not pay taxes and take a huge cut of the proceeds of funerals held there. The young entrepreneur decided to supply marble tombstones to the temples, importing them from China “to fix my foreign exchange problem”.
Golden Meditech describes itself as a leading integrated healthcare company in China, a sector that “needs government support and is in line with government policy”. The founder points out: “I don’t compete with the state-owned institutions. My customers are high end.”
The company includes the first nationwide hospital management operator in China that is wholly foreign owned, as well as a medical devices segment.
During the year ended March 2012 profit after tax dropped 48 per cent to HK$84m, a decline Mr Kam attributes to the volatility of financial markets. Given his own confidence in the business and a sense that current stock prices fail to reflect the intrinsic value of Golden Meditech, he told shareholders in June that he was increasing his own stake to 22.2 per cent.
Like so many companies in China, Golden Meditech is a one-man show. Disconcertingly from the point of view of corporate governance purists, Mr Kam is chairman, chief executive and chief compliance officer. To him that makes perfect sense.
Source: FT

Shortage of vaccines for tetanus and pertussis in China

Shortages of tetanus and pertussis vaccine may affect people living in China
Why is there a shortage of tetanus vaccine in China?
The local manufacturer of Tetanus-diphtheria vaccine (Td) does not plan to continue producing this vaccine, at least until mid 2013, due to low demand of use in China. The low demand is mainly because the China immunization schedule does not include the 10 years booster for all adults. Tetanus vaccine for children is still in the China immunisation schedule. It is offered as DTaP and DT for different ages of children.

What can be done if I had an accident causing open and dirty wounds and I know I do not have tetanus immunity?
[Our hospital] has the tetanus immunoglobulin that our doctor can administer intramuscularly to prevent possible tetanus infection.

What is the reason for the shortage Tdap (Boostrix) vaccine?
Boostrix is manufactured by GSK Belgium. This imported vaccine is discontinued in the China market, but still available globally elsewhere.

How soon are these vaccine shortages going to affect us?
Very soon. Remaining stock of Td vaccine expires on December 23rd, 2012; remaining Tdap (Boostrix) stock expires on January 31st, 2013.

Who will be most affected by the Boostrix shortage?
Adolescents and adults (i.e. parents, siblings, grandparents, childcare providers and healthcare personnel) who have or anticipate having close contact with infants younger than 12 months of age and pregnant women who previously have not received Tdap. US Advisory Committee on Immunization Practices (ACIP) recommends this group of people to be vaccinated against pertussis (also known as whooping cough) with Tdap vaccine (Boostrix), because pertussis causes high risk of pneumonia and death in young infants, especially < 3 months-old if infected.
Source: United Healthcare Shanghai

China launches national anti-smoking plan

Anti-smoking plan aims to cut China's smoking rate to 25% of population by 2015
China has published a plan to reduce the world’s largest population of smokers as part of a 2005 treaty, without implementing recommendations such as warning labels that include photos of rotten teeth and diseased lungs.
China plans to cut the number of smokers to 25 percent of the population by 2015 from 28.1 percent in 2010, according to the plan published by the Ministry of Industry and Information Technology yesterday, seven years after the country signed the treaty that recommends the graphic warning labels.
The government will “comprehensively” prohibit smoking in public places and ban ads, promotion and sponsorship by tobacco companies, according to the plan. There is no mention of tax rates in the plan.
China has more than 300 million smokers, including half the adult male population, and about 740 million people are exposed to second-hand smoke risks, the ministry said. The tobacco industry accounts for 20 million jobs and contributed 6 percent of fiscal revenues in 2010, the ministry said.
“The plan carries a heavy smell of cigarettes,” Wu Yiqun, a director at the Beijing-based ThinkTank Research Center for Health Development. “It’s a compromise result between the tobacco industry and the Health Ministry, and it seems the tobacco side has the upper hand.” The State Tobacco Monopoly Administration was involved in the plan’s preparation.
Wu, a former deputy director at the Chinese Center for Disease Control and Prevention, singled out the lack of graphic photos as a weakness. Australia, Canada and most European Union members have introduced such warnings or have agreed to do so, according to the World Health Organization website.
“It means China’s tobacco control efforts will be weak compared to mainstream international practices,” Wu said. The lack of any plan to increase taxes on tobacco is another weakness, she said.
The WHO recommended in March that China should almost triple excise taxes on tobacco products to 70 percent from 26 percent, to dissuade young people from taking up the habit. Half of the country’s smokers spend 5 yuan (80 cents) or less for a packet of 20 cigarettes, the WHO said.
Smoking, which is linked to 1 million deaths a year in China, is endangering the labor force, Health Minister Chen Zhu said in April.
Using cigarettes as gifts or gestures of friendship is still a popular practice in the country, and many poor regions rely on the industry to generate jobs and fiscal revenue, the industry ministry said.
Cigarette production and consumption in China both increased by 3 percent last year, according to data from Bloomberg Industries. China’s share of world cigarette consumption increased to 40 percent last year from 35 percent in 2006. Consumption in the rest of the world has declined steadily since 2000.
The brother of Chinese Vice Premier Li Keqiang should be removed from his post as a top official in China’s state-owned tobacco monopoly to avoid conflicts of interest, according to a report published by the Washington-based Brookings Institution in October. Li last month took the No.2 position in China’s new leadership and is now oversees public health.
China’s new tobacco plan was jointly prepared by the ministries of industry, health, finance and foreign affairs; and the general administrations of tobacco, customs, safety and industry and commerce.
Source: Bloomberg

Sunday, 23 December 2012

Use of new liver cancer drug sorafenib doubles

Use of Nexavar (sorafenib, from Bayer and Onyx Pharmaceuticals) has nearly doubled in first-line advanced hepatocellular carcinoma (HCC) patients in China in 2012 from 2011, according to new findings.
“Nexavar quickly became the standard of care for HCC in Western markets when it was first approved five years ago; however, Chinese physicians have historically relied on 5-FU-based regimens,” said Neesha Suvarna, a consultant with Kantar Health, adding: “Our most recent physician survey data shows that Nexavar adoption is increasing in China. While the utilization of Nexavar in HCC is smaller in China compared with the West, the growth trend we observe suggests that there is a high potential for growth.”
In addition, Kantar Health’s research found that use of Alimta (pemetrexed, from Eli Lilly is gradually increasing in non-squamous non-small cell lung cancer (NSCLC) patients in China since its approval in 2011. Also gaining in use are EGFR biomarker testing and EGFR-targeting agents, such as Tarceva (erlotinib, Genentech/Roche/Astellas) and Iressa (gefitinib, AstraZeneca) in Chinese patients who are EGFR-mutant.
Chinese doctors slowly adopting Western treatment practices
“China has traditionally faced a drug approval and adoption lag, and our recent data suggests that Chinese physicians are slowly adopting Western treatment practices,” said Dr Suvarna, adding: “There are multiple barriers to adoption, including the high price of agents and lack of reimbursement. However, support from patient access programs, increasing patient education and availability of cheaper drugs or generics might all play a role in slowly revolutionizing treatment practices in China.”
Source: Pharma Letter

Saturday, 22 December 2012

China will drive growth in interventional cardiology

The Asia Pacific interventional cardiology market will grow at a strong average rate of 12% per year through 2017, with growth driven by China, a new report claims.
Most of this growth will come from increased numbers of procedures in China and India, while procedural growth in Australia and South Korea will be flat, according to Millennium Research Group. Competition and reimbursement restrictions will push average selling prices (ASP) down in all national markets.
The United States and Europe will also see flat procedural growth and declining ASPs. As a result, manufacturers are looking to India and China for market expansion and revenue growth. Both countries have a large population base with increasing disposable incomes and increasing rates of diseases such as coronary artery disease (CAD), diabetes and hypertension that increase the number of required coronary interventions.
There are a number of obstacles to expansion in these markets, however. China, for example, has a number of strong local competitors, with the majority of revenue going to local companies such as Ji Wei and Lepu Medical. Local companies tend to offer considerably cheaper devices, and have good long-term relationships with hospitals and doctors. Foreign companies are increasingly making attempts to level the playing field in China by creating local manufacturing, local training centers, expanding their sales force, or through mergers and acquisitions.
“China is a particularly strong adopter of drug-eluting stents (DES),” said MRG Analyst Mirel Giugaru. “DES are the biggest revenue earners in any interventional cardiology market. Patients are becoming highly aware of DES, and perceive them as the best available treatment option, creating strong demand. A number of local competitors offer DES in China, so penetration of the technology is high. In India, by contrast, DES adoption is lower, because the price of the devices is unaffordable for a large segment of the population.”
Prices in China will continue to drop as the government increasingly relies on local tendering systems to control costs. Sources indicate that it is planning to cut DES prices by about 15 percent in the near future.
Millennium Research Group’s Asia Pacific Markets for Interventional Cardiology Devices 2013 report includes unit, installed base, average selling price and revenue information, along with market drivers and limiters and competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, and accessory devices sold in Australia, China, India and South Korea.
Read more:
PharmiWeb

China-US joint venture for Clinical Research Organisations

WuXi PharmaTech, the contract research organisation with operations in China and the US, is forming a joint venture with fellow CRO PRA to provide a broad range of Phase I-IV clinical-trial services in the Chinese market, including Hong Kong and Macau.
The two companies will combine their respective clinical operations into an independent contract research organisation jointly owned by its parents. Among the services on offer are clinical-trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug-safety reporting and medical monitoring.
WuXi will contribute clinical and regulatory experience from its China-based clinical organisation, which covers all regions of the country and has employees working in 16 Chinese cities, as well as offices in Shanghai, Beijing and Guangzhou.
The company will also supply laboratory services to the joint venture through a preferred-provider arrangement.
PRA will bring to the joint venture “a wealth of global resources and clinical-research expertise, reflected in more than 3,100 studies conducted over the last five years and contributions to 40 approved drugs in several therapeutic areas”, the partners noted.
The US-headquartered CRO will also support the venture with its staff based in China and its global technology capabilities, encompassing data capture, trial management and other information-technology systems.
WuXi and PRA will market the joint venture’s services to their respective customers.
“PRA’s global experience and technical expertise and WuXi’s operational experience and knowledge in China are a perfect fit,” commented Colin Shannon, president and chief executive (CEO) of PRA.
Dr Ge Li, chairman and CEO of WuXi PharmaTech, said the two companies were building “the leading clinical-trial services operation in China”.
The local pharmaceutical market is the now the third largest in the world and is “growing very rapidly”, he added.
“Biopharmaceutical companies increasingly need sophisticated clinical-trial management services to gather the highest-quality data in Chinese patients to complete Chinese and international regulatory filings as quickly and successfully as possible.”
PRA recently opened a second office in China to accommodate its continued growth in that country and the wider Asia Pacific region.
Source: Pharma Times

China poised to become biopharm giant

by Grace Ng
In November 2010, a bold prediction that China was poised to become the global leader in life sciences innovation by 2020 was met with incredulity from many in the West.
"When our thought paper was published, the reaction from people in charge of R&D in the US and Europe was typically: "Oh, you must be kidding"," recalled George Baeder, who was leading consultancy Monitor Group's Asia life sciences practice at the time.
Others, who were more aware of the rapid changes in China, figured this scenario could well take place - in 20 to 30 years.
Two years later, few are resisting the idea any more.
"It's quite the reverse - there is a real focus on Western companies figuring out how to participate in the shift to China that is underway," said Mr Baeder, now senior vice-president of Asia Pacific consulting at Quintiles. "If anything, it's happening faster."
In recent years, virtually every big-name pharmaceutical firm has started R&D operations here.
Among them are Merck Sharp &Dohme, which plans to invest US$1.5 billion in R&D here over the next five years, and Bayer Healthcare, which moved the global authority for its primary care business from Berlin to Beijing.
And to serve the burgeoning demand from both local and multinational firms in China for services from managing clinical trials to preparing regulatory submissions and biostatistics, Quintiles has set up a US$14 million headquarters in Shanghai in June, among other expanded facilities.
China's draw lies not just in its massive health-care demand.
Analysts say firms can potentially invent, test and bring a drug to market faster and more cheaply here than in the West.
"China's talent and cost advantages are the reasons for more Western giants expanding here," said market trends company Zero2IPO group general manager Feng Suqiang.
The world's No 2 economy is building up a pool of China-born, Western-trained life sciences PhD holders to drive the sector.
At least 80,000 such scientists have already returned to China, according to the 2010 Monitor report, which predicted an acceleration of this trend.
Meanwhile, the local authorities are dangling preferential rental and tax rates on cutting-edge facilities to house brand-name or promising companies.
At least a dozen local governments from Shijiazhuang city in the north to Suzhou in the south have set up biotech parks of late, up from just five in 2010.
But what could really prove to be China's advantages as a biotech hub is the recent launch of new products such as Conmana.
A cancer drug entirely developed in China by Zhejiang Beta Pharma, Conmana has drawn attention after being shown to be faster-acting and more effective than a foreign anti-cancer drug in comparative trials. It reportedly took just six years to be developed and brought to the market, at a cost of only about $30 million.
In contrast, the average cost of developing an approved drug in the traditional way is over $1.9 billion and clinical trials can take 13.5 years, according to a report this month by Office of Health Economics, a British think-tank.
Mr Baeder expects that when word gets out about Beta Pharma's more cost-effective process, potentially through a stock market listing next year, the "financial community is suddenly going to see a completely different way of developing products".
The traditional model has typically started with developing a drug in the West and then conducting clinical trials across a few dozen markets - a large-scale process that jacks up costs.
But now, firms may opt to conduct the whole process in China, which offers the largest population on Earth for collecting clinical trial data, and the biggest market in many drug categories.
And a poster boy for this new model is Beta Pharma. Its successful listing could help convince investors that China has the potential to create a more vigorous pipeline of new products.
This in turn could spark "a stampede of companies trying to figure out how to leverage China as the focal point for new product development", said Mr Baeder.
And it may not be too long before China makes the next breakthrough discovery.
"One notable area where China is already making certain headway globally is in genome sequencing," pointed out Lin Hui-Yi, the China research head for consultancy Grail Research.
Baeder added that China could see the creation of "truly innovative medicine being used to treat patients as part of clinical trials within the next six to seven years".
Still, some analysts, such as Feng, are sceptical.
China has the talent and technology, but lacks the capital to create a breakthrough product, he noted. "A widespread problem for Chinese firms is that their financial clout is insufficient."
Enter state funding.
Beijing has pledged to raise funding for life sciences to 2 trillion yuan ($320 billion) up to 2015.
And some local governments are playing venture capitalists to support biotech firms. Among the latest ventures is the 250 million yuan Henan Broadhi Biological Fund, which counts the Henan provincial government and China's top economic planning agency as key investors.
All this has also whetted the appetite of private investors.
In the first half of this year, eight private equity deals in China's biomed sector worth $620 million were inked, two-thirds of the $953 million invested for the whole of last year, said consultancy AVCJ Research.
Read more: China Daily

Friday, 21 December 2012

Chinese trial results sink hopes for niacin as lipid therapy

Niacin (Tredaptive) caused higher rates of myopathy in Chinese patients
Results from a Chinese trial have forced Merck to drop plans to seek U.S. regulatory approval for the lipid modifying drug niacin after it failed to reduce the risk of heart attacks and strokes, while increasing the risk of adverse health events.
The company also recommended doctors not start new patients on the combination of niacin and an anti-flushing drug (Tredaptive) in the approximately 40 countries where it is sold outside the U.S.
The negative outcome deals a blow to Merck, which has been trying to bring new drugs to market to help offset patent expirations for top drugs that have triggered sales-eroding generic competition.
The drug's failure also reinforces questions about the effectiveness of niacin - the key component of Tredaptive, as well as the broader strategy of seeking to raise levels of good cholesterol as a way to combat cardiovascular disease.
Tredaptive is a single-pill combination of niacin, a B vitamin that has been available for more than half a century, with a Merck-developed compound called laropiprant. Niacin is known primarily for increasing levels of good cholesterol, which theoretically should help ward off heart attacks and other cardiovascular events. Niacin also has been shown to lower bad cholesterol and triglycerides, a fatty substance in the bloodstream.
Laropiprant is designed to inhibit a common side effect of niacin, a reddening of the skin known as flushing.
Merck believed the flushing side effect has hampered the use of niacin and that combining it with laropiprant would make the drug more palatable to patients.
Merck initially applied in 2007 for U.S. Food and Drug Administration approval of Tredaptive, based on studies showing it improved cholesterol levels and inhibited flushing. But the FDA declined to approve it, asking Merck to wait for the outcome of a study called "HSP2-Thrive."
HPS2-Thrive tested whether adding Tredaptive to a regimen including simvastatin—which belongs to an older class of cholesterol-lowering drugs known as statins—reduces cardiovascular risk compared with the statin therapy alone.
The University of Oxford's clinical trial service unit conducted the HPS2-Thrive study, which enrolled about 25,670 patients at high risk of heart attack and related cardiovascular events. Of those enrolled, 14,741 were from Europe—the U.K. and Scandinavia—and 10,932 were from China, Merck said. Patients in the study were followed for a median of 3.9 years.
Merck said Thursday that Tredaptive plus statin therapy didn't significantly reduce the risk of the combination of coronary deaths, nonfatal heart attacks, strokes or procedures known as revascularizations, compared with statin therapy.
There was a statistically significant increase in the incidence of some types of nonfatal serious adverse events in the group that received Tredaptive.
The Oxford Clinical Trial Service Unit said in a separate statement posted online that it would present full results in the first quarter of 2013. One of the study investigators, Richard Haynes, said: "It has long been known that niacin causes a number of side effects, and the HPS2-Thrive study allows these to be explored in more detail."
The Oxford researchers earlier said that the Chinese patients seemed to be more prone to myopathy with niacin
Source: WSJ

Bribing of Chinese doctors costs Eli Lilly a $29 million fine

In the latest instance in which a drugmaker was caught making bribes overseas, Eli Lilly was charged by the US Securities and Exchange Commission with violating the Foreign Corrupt Practices Act because its subsidiaries made improper payments to foreign government officials to win millions of dollars of business in China as well as Russia, Brazil, and Poland.
The FCPA forbids US companies from bribing foreign government officials. However, in China, employees at the Lilly falsified expense reports in order to provide spa treatments, jewelry, and other improper gifts and cash payments to government-employed physicians.
A Lilly subsidiary in Russia used offshore “marketing agreements” to pay more than $7 millions to third parties chosen by government customers or distributors, despite knowing little or nothing about the third parties beyond their offshore address and bank account information, according to an SEC statement.
The SEC alleges Lilly became aware of possible FCPA violations, but did not curtail the use of marketing agreements for more than five years. Lilly subsidiaries in Brazil, China, and Poland also made improper payments to government officials or third-party entities associated with government officials. Lilly agreed to pay more than $29 million to settle the SEC’s charges.
Read more: Pharmalot

Shenzhen gene sequencers find clues to autism

Shenzhen's BGI genome centre has found mutation hotspots in people with autism
An international team, including a Shenzhen-based gene sequencing company, has discovered that "random" mutations in the genome are not quite so random after all. 
Their study, to be published in the journal Cell on December 21, shows that the DNA sequence in some regions of the human genome is quite volatile and can mutate ten times more frequently than the rest of the genome. Genes that are linked to autism and a variety of other disorders have a particularly strong tendency to mutate.
Clusters of mutations or "hotspots" are not unique to the autism genome but instead are an intrinsic characteristic of the human genome, according to principal investigator Jonathan Sebat, PhD, professor of psychiatry and cellular and molecule medicine, and chief of the Beyster Center for Molecular Genomics of Neuropsychiatric Diseases at UC San Diego.
"Our findings provide some insights into the underlying basis of autism—that, surprisingly, the genome is not shy about tinkering with its important genes" said Sebat. "To the contrary, disease-causing genes tend to be hypermutable."
Sebat and collaborators from Rady Children's Hospital-San Diego and BGI genome center in China sequenced the complete genomes of identical twins with autism spectrum disorder and their parents. When they compared the genomes of the twins to the genomes of their parents, the scientists identified many "germline" mutations (genetic variants that were present in both twins but not present in their mother or father).
Nearly 600 germline mutations – out of a total of 6 billion base pairs – were detected in the 10 pairs of identical twins sequenced in the study. An average of 60 mutations was detected in each child.
"The total number of mutations that we found was not surprising," said Sebat, "it's exactly what we would expect based on the normal human mutation rate." What the authors did find surprising was that mutations tended to cluster in certain regions of the genome. When the scientists looked carefully at the sites of mutation, they were able to determine the reasons why some genomic regions are "hot" while other regions are cold.
"Mutability could be explained by intrinsic properties of the genome," said UC San Diego postdoctoral researcher Jacob Michaelson, lead author of the study. "We could accurately predict the mutation rate of a gene based on the local DNA sequence and its chromatin structure, meaning the way that the DNA is packaged."
The researchers also observed some remarkable examples of mutation clustering in an individual child, where a shower of mutations occurred all at once. "When multiple mutations occur in the same place, such an event has a greater chance of disrupting a gene," said Michaelson.
The researchers surmised that hypermutable genes could be relevant to disease. When they predicted the mutation rates for genes, the authors found that genes that have been linked to autism were more mutable than the average gene, suggesting that some of the genetic culprits that contribute to autism are mutation hotspots.
The authors observed a similar trend for other disease genes. Genes associated with dominant disorders tended to be highly mutable, while mutation rates were lower for genes associated with complex traits.
Read more: Eurekalert